Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246225 | 0.98 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1KDM4E | |
| Methyl Alcohol SCHEMBL27842799 | 0.95 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL12487855 | 0.95 | KDM4E (0.37) | MEN1KMT2AHTTL3MBTL1KDM4E | |
| Carbamic Acid SCHEMBL30900855 | 0.93 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1KDM4E | |
| Acetonitrile SCHEMBL30270573 | 0.88 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL16767521 | 0.85 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL838329 | 0.84 | KMT2A (0.36) | MEN1KMT2AHTTL3MBTL1KDM4E | |
| SCHEMBL838138 | 0.83 | CHRM2 (0.38) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2121005 | 0.81 | CHRM2 (0.41) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL22716834 | 0.81 | CHRM2 (0.37) | MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131412-A1 | NOVEL 2-QUINOLONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1908752-A1 | NOVEL 2-QUINOLONE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131412-A1 | NOVEL 2-QUINOLONE DERIVATIVE | SCN1B, OPRL1, SCN1A | MEN1 1992/4885KMT2A 2423/4885HTT 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.